

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent	12383689
Kind Code	B2
Date of Patent	August 12, 2025
Inventor(s)	Tatkov; Stanislav

Asymmetrical nasal delivery elements and fittings for nasal interfaces

Abstract

A nasal interface uses asymmetrical nasal delivery elements to deliver an asymmetrical flow through the interface to both nares or to either nare, and a mouthpiece may be inserted to maintain a leak, to improve dead space clearance in the upper airways, decrease peak expiratory pressure, reduce noise, increase safety of the therapy for smaller patients and reduce resistance in the interface allowing desired flow rates to be achieved at reduced motor speeds of associated flow generating devices. Different forms of fittings, such as sleeves or inserts can be attached to nasal delivery elements to improve or optimize the therapeutic effects of nasal high flow. It may allow high pressures to be achieved at lower flow rates, reduce noise, improve patient comfort and efficiently clear anatomical dead space.

Inventors:	Tatkov; Stanislav (Auckland, NZ)
Applicant:	Fisher & Paykel Healthcare Limited (Auckland, NZ)
Family ID:	1000008748893
Assignee:	Fisher & Paykel Healthcare Limited (Auckland, NZ)
Appl. No.:	18/146298
Filed:	December 23, 2022

Prior Publication Data

Document Identifier	Publication Date
US 20230211104 A1	Jul. 06, 2023

Related U.S. Application Data

continuation parent-doc US 16798005 20200221 US 11565067 child-doc US 18146298
continuation parent-doc US 14907510 US 10569043 20200225 WO PCT/NZ2014/000163
20140808 child-doc US 16798005

Publication Classification

Int. Cl.: A61M16/06 (20060101); A61M16/00 (20060101); A61M16/10 (20060101)

U.S. Cl.:

CPC A61M16/0672 (20140204); A61M16/0683 (20130101); A61M16/0688 (20140204); A61M2016/0027 (20130101); A61M2016/003 (20130101); A61M2016/1025 (20130101); A61M2016/103 (20130101); A61M2202/0208 (20130101); A61M2202/0225 (20130101); A61M2205/42 (20130101); A61M2206/20 (20130101); A61M2230/205 (20130101); A61M2230/432 (20130101); A61M2230/435 (20130101); A61M2240/00 (20130101); A61M2202/0208 (20130101); A61M2202/0007 (20130101); A61M2202/0225 (20130101); A61M2202/0085 (20130101)

Field of Classification Search

CPC: A61M (16/0666-0672); A61M (16/0683); A61M (16/0688); A61M (2016/0027); A61M (2016/003); A61M (2016/1025); A61M (2016/103); A61M (2202/0208); A61M (2202/0225); A61M (2205/42); A61M (2206/20); A61M (2230/205); A61M (2230/432); A61M (2230/435); A61M (2240/00); A61F (5/56); A61F (5/08); A62B (23/06); Y10T (137/789)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
362664	12/1886	Rothwell	N/A	N/A
1229050	12/1916	Donald	N/A	N/A
1248558	12/1916	Scribner	N/A	N/A
2168705	12/1938	Francisco et al.	N/A	N/A
2245969	12/1940	Francisco et al.	N/A	N/A
2366067	12/1943	Smith	N/A	N/A
2499650	12/1949	Kaslow	N/A	N/A
2663297	12/1952	Turnberg	N/A	N/A
2693800	12/1953	Caldwell	N/A	N/A
2735432	12/1955	Hudson	N/A	N/A
2868199	12/1958	Hudson	N/A	N/A
2902737	12/1958	Moran	N/A	N/A
2918314	12/1958	Kemintz	N/A	N/A
2962884	12/1959	Garrou et al.	N/A	N/A
3161199	12/1963	Sands	N/A	N/A
3288136	12/1965	Lund	N/A	N/A
3400196	12/1967	Leroy	N/A	N/A
3510155	12/1969	Jacobus	N/A	N/A
3570482	12/1970	Emoto et al.	N/A	N/A
3585692	12/1970	Mire	N/A	N/A

3650867	12/1971	Bauer	N/A	N/A
3682171	12/1971	Dali et al.	N/A	N/A
3702612	12/1971	Schlesinger	N/A	N/A
3754552	12/1972	King	N/A	N/A
3799164	12/1973	Rollins	N/A	N/A
3858615	12/1974	Weigl	N/A	N/A
3877436	12/1974	Havstad	N/A	N/A
3972321	12/1975	Proctor	N/A	N/A
4000341	12/1975	Matson	N/A	N/A
4106505	12/1977	Salter et al.	N/A	N/A
4142527	12/1978	Garcia	N/A	N/A
4152017	12/1978	Abramson	N/A	N/A
4177945	12/1978	Schwartz et al.	N/A	N/A
4216769	12/1979	Grimes	N/A	N/A
4248218	12/1980	Fischer	N/A	N/A
4273124	12/1980	Zimmerman	N/A	N/A
4282871	12/1980	Chodorow et al.	N/A	N/A
4284076	12/1980	Hall	N/A	N/A
4316458	12/1981	Hammerton- Fraser	N/A	N/A
4328797	12/1981	Rollins, III et al.	N/A	N/A
4367735	12/1982	Dali	N/A	N/A
4422456	12/1982	Tiep	N/A	N/A
4441494	12/1983	Montalbano	N/A	N/A
4454880	12/1983	Muto et al.	N/A	N/A
4457544	12/1983	Snow et al.	N/A	N/A
4463755	12/1983	Suzuki	N/A	N/A
4586273	12/1985	Chapnick	N/A	N/A
4648398	12/1986	Agdanowski et al.	N/A	N/A
4648923	12/1986	Chapnick	N/A	N/A
4653542	12/1986	Tascher	N/A	N/A
4660055	12/1986	Payton	N/A	N/A
4676241	12/1986	Webb et al.	N/A	N/A
4685456	12/1986	Smart	N/A	N/A
4753233	12/1987	Grimes	N/A	N/A
4782832	12/1987	Trimble et al.	N/A	N/A
4808160	12/1988	Timmons et al.	N/A	N/A
4831694	12/1988	Kong	N/A	N/A
4832010	12/1988	Lerman	N/A	N/A
4838258	12/1988	Dryden et al.	N/A	N/A
4875718	12/1988	Marken	N/A	N/A
4913471	12/1989	Huneke	N/A	N/A
4915105	12/1989	Lee	N/A	N/A
4919128	12/1989	Kopala et al.	N/A	N/A
4933231	12/1989	Seber	N/A	N/A
4995384	12/1990	Keeling	N/A	N/A
5005571	12/1990	Dietz	N/A	N/A
5009227	12/1990	Nieuwstad	N/A	N/A
5025805	12/1990	Nutter	N/A	N/A

5042478	12/1990	Kopala et al.	N/A	N/A
5046200	12/1990	Feder	N/A	N/A
5139476	12/1991	Peters	N/A	N/A
5156641	12/1991	White	N/A	N/A
5178163	12/1992	Yewer, Jr.	N/A	N/A
5183059	12/1992	Leonardi	N/A	N/A
5222486	12/1992	Vaughn	N/A	N/A
5308337	12/1993	Bingisser	N/A	N/A
5335656	12/1993	Bowe et al.	N/A	N/A
5399153	12/1994	Caprio, Jr. et al.	N/A	N/A
5400776	12/1994	Bartholomew	N/A	N/A
5429126	12/1994	Bracken	N/A	N/A
5438979	12/1994	Johnson, Jr. et al.	N/A	N/A
5478123	12/1994	Kanao	N/A	N/A
5485850	12/1995	Dietz	N/A	N/A
5487571	12/1995	Robertson	N/A	N/A
5507535	12/1995	McKamey et al.	N/A	N/A
5509409	12/1995	Weatherholt	N/A	N/A
5513635	12/1995	Bedi	N/A	N/A
5533506	12/1995	Wood	N/A	N/A
5572994	12/1995	Smith	N/A	N/A
5656023	12/1996	Caprio, Jr. et al.	N/A	N/A
5682881	12/1996	Winthrop et al.	N/A	N/A
5704916	12/1997	Byrd	N/A	N/A
5724677	12/1997	Bryant et al.	N/A	N/A
5724965	12/1997	Handke et al.	N/A	N/A
5802620	12/1997	Chiang	N/A	N/A
5934276	12/1998	Fabro et al.	N/A	N/A
6003213	12/1998	Keller et al.	N/A	N/A
6017315	12/1999	Starr et al.	N/A	N/A
6019101	12/1999	Cotner et al.	N/A	N/A
6070579	12/1999	Bryant et al.	N/A	N/A
6109101	12/1999	Iwabuchi et al.	N/A	N/A
6119693	12/1999	Kwok et al.	N/A	N/A
6119694	12/1999	Correa et al.	N/A	N/A
6123077	12/1999	Bostock et al.	N/A	N/A
6148929	12/1999	Winters	N/A	N/A
6219490	12/2000	Gibertoni et al.	N/A	N/A
6270127	12/2000	Enderle	N/A	N/A
6318364	12/2000	Ford et al.	N/A	N/A
6328038	12/2000	Kessler et al.	N/A	N/A
6347631	12/2001	Hansen et al.	N/A	N/A
6367510	12/2001	Carlson	N/A	N/A
6374826	12/2001	Gunaratnam et al.	N/A	N/A
6386198	12/2001	Rugless	N/A	N/A
6415788	12/2001	Clawson et al.	N/A	N/A
6415789	12/2001	Freitas et al.	N/A	N/A
6418928	12/2001	Bordewick et al.	N/A	N/A

6418929	12/2001	Norfleet	N/A	N/A
6431172	12/2001	Bordewick et al.	N/A	N/A
6434796	12/2001	Speirs	N/A	N/A
6505624	12/2002	Campbell, Sr.	N/A	N/A
6508249	12/2002	Hoening	N/A	N/A
6561193	12/2002	Noble	N/A	N/A
6615830	12/2002	Serowski et al.	N/A	N/A
6733046	12/2003	Rief	N/A	N/A
6769431	12/2003	Smith et al.	N/A	N/A
6779522	12/2003	Smith et al.	N/A	N/A
6796310	12/2003	Bierman	N/A	N/A
6799575	12/2003	Carter	N/A	N/A
6807966	12/2003	Wright	N/A	N/A
6807967	12/2003	Wood	N/A	N/A
6986353	12/2005	Wright	N/A	N/A
6994089	12/2005	Wood	N/A	N/A
7089939	12/2005	Walker et al.	N/A	N/A
7140366	12/2005	Smith et al.	N/A	N/A
7146976	12/2005	McKown	N/A	N/A
7147252	12/2005	Teuscher et al.	N/A	N/A
7152597	12/2005	Bathe	N/A	N/A
7152604	12/2005	Hickle et al.	N/A	N/A
7156096	12/2006	Landis	N/A	N/A
7156097	12/2006	Cardoso	N/A	N/A
7156127	12/2006	Moulton et al.	N/A	N/A
7174893	12/2006	Walker et al.	N/A	N/A
7201169	12/2006	Wilkie et al.	N/A	N/A
7225811	12/2006	Ruiz et al.	N/A	N/A
7296575	12/2006	Radney	N/A	N/A
7318463	12/2007	Tanaka et al.	N/A	N/A
7353826	12/2007	Sleeper et al.	N/A	N/A
7370652	12/2007	Matula, Jr. et al.	N/A	N/A
7396995	12/2007	Laurent et al.	N/A	N/A
7458615	12/2007	White et al.	N/A	N/A
7458938	12/2007	Patel et al.	N/A	N/A
7476212	12/2008	Spearman et al.	N/A	N/A
D586911	12/2008	McAuley et al.	N/A	N/A
7493902	12/2008	White et al.	N/A	N/A
7556043	12/2008	Ho et al.	N/A	N/A
7665465	12/2009	Radney	N/A	N/A
7735490	12/2009	Rinaldi	N/A	N/A
7775210	12/2009	Schobel et al.	N/A	N/A
7779832	12/2009	Ho	N/A	N/A
7856982	12/2009	Matula, Jr. et al.	N/A	N/A
7874293	12/2010	Gunaratnam et al.	N/A	N/A
7900628	12/2010	Matula, Jr. et al.	N/A	N/A
7942150	12/2010	Guney et al.	N/A	N/A
RE42843	12/2010	Srickland et al.	N/A	N/A
8028692	12/2010	Ho	N/A	N/A

8042546	12/2010	Gunaratnam et al.	N/A	N/A
8056558	12/2010	Bracken	N/A	N/A
8136524	12/2011	Ging et al.	N/A	N/A
8136525	12/2011	Lubke et al.	N/A	N/A
8161971	12/2011	Jaffe et al.	N/A	N/A
8171935	12/2011	Cortez, Jr. et al.	N/A	N/A
8192421	12/2011	Lopez et al.	N/A	N/A
8216845	12/2011	Ajiro et al.	N/A	N/A
8220463	12/2011	White et al.	N/A	N/A
8286635	12/2011	Carroll et al.	N/A	N/A
8317755	12/2011	Morrison et al.	N/A	N/A
8453681	12/2012	Forrester et al.	N/A	N/A
D685463	12/2012	Veliss et al.	N/A	N/A
8474461	12/2012	Masella et al.	N/A	N/A
8517022	12/2012	Halling et al.	N/A	N/A
8596263	12/2012	Piper	N/A	N/A
8596271	12/2012	Matula, Jr. et al.	N/A	N/A
8613739	12/2012	Sobue	N/A	N/A
8616203	12/2012	Jaffe et al.	N/A	N/A
8636007	12/2013	Rummery et al.	N/A	N/A
8667964	12/2013	Ho	N/A	N/A
8701667	12/2013	Ho et al.	N/A	N/A
8701668	12/2013	Selvarajan et al.	N/A	N/A
8757162	12/2013	Veliss et al.	N/A	N/A
8789528	12/2013	Carter et al.	N/A	N/A
D717942	12/2013	Neff et al.	N/A	N/A
D724720	12/2014	O'Connor et al.	N/A	N/A
8985117	12/2014	Gunaratnam et al.	N/A	N/A
8997747	12/2014	Hobson et al.	N/A	N/A
9044562	12/2014	Dillingham et al.	N/A	N/A
9067035	12/2014	Ophir et al.	N/A	N/A
9132256	12/2014	Gunaratnam et al.	N/A	N/A
9138554	12/2014	Colbaugh	N/A	N/A
D747461	12/2015	Tam et al.	N/A	N/A
D747794	12/2015	Greenberg et al.	N/A	N/A
9227033	12/2015	Smart	N/A	N/A
9272114	12/2015	Herron	N/A	N/A
9308698	12/2015	Forrester et al.	N/A	N/A
D756817	12/2015	Fries et al.	N/A	N/A
D757250	12/2015	Veliss et al.	N/A	N/A
D760379	12/2015	Smith et al.	N/A	N/A
9365004	12/2015	Forrester	N/A	N/A
9393375	12/2015	Hernandez et al.	N/A	N/A
D764049	12/2015	Cullen et al.	N/A	N/A
9480809	12/2015	Guney et al.	N/A	N/A
D776252	12/2016	Hoke et al.	N/A	N/A
9539404	12/2016	McAuley et al.	N/A	N/A

9550038	12/2016	McAuley et al.	N/A	N/A
D779432	12/2016	Wong et al.	N/A	N/A
9561339	12/2016	McAuley et al.	N/A	N/A
9561340	12/2016	Guney et al.	N/A	N/A
9649463	12/2016	Ho et al.	N/A	N/A
9675774	12/2016	Cipollone et al.	N/A	N/A
9707010	12/2016	Koeth	N/A	N/A
9750915	12/2016	Opperman et al.	N/A	N/A
9814854	12/2016	Chua	N/A	N/A
9827392	12/2016	Lei	N/A	N/A
9884160	12/2017	McAuley et al.	N/A	N/A
9895505	12/2017	Guney	N/A	N/A
9925348	12/2017	Payton et al.	N/A	N/A
9943660	12/2017	Selvarajan et al.	N/A	N/A
9962512	12/2017	Cipollone et al.	N/A	N/A
10029063	12/2017	Barlow	N/A	N/A
10034995	12/2017	Kooij et al.	N/A	N/A
10105099	12/2017	Jaffe et al.	N/A	N/A
10159812	12/2017	Varga	N/A	N/A
10166359	12/2018	Breckon	N/A	N/A
D852053	12/2018	Kimm et al.	N/A	N/A
10350379	12/2018	Sweeney et al.	N/A	N/A
11565067	12/2022	Tatkov	N/A	A61M 16/0683
2001/0015204	12/2000	Hansen et al.	N/A	N/A
2001/0029954	12/2000	Palmer	N/A	N/A
2002/0014241	12/2001	Gradon et al.	N/A	N/A
2002/0026934	12/2001	Lithgow et al.	N/A	N/A
2002/0157672	12/2001	Gunaratnam et al.	N/A	N/A
2003/0116963	12/2002	Teuscher et al.	N/A	N/A
2004/0065330	12/2003	Landis	N/A	N/A
2004/0130150	12/2003	Stark	N/A	N/A
2004/0216747	12/2003	Jones, Jr. et al.	N/A	N/A
2004/0261797	12/2003	White et al.	N/A	N/A
2005/0028822	12/2004	Sleeper et al.	N/A	N/A
2005/0066964	12/2004	Bathe	N/A	N/A
2005/0121038	12/2004	Christopher	N/A	N/A
2005/0277821	12/2004	Payne, Jr.	N/A	N/A
2006/0231100	12/2005	Walker et al.	N/A	N/A
2007/0157932	12/2006	Cerbini	N/A	N/A
2007/0175480	12/2006	Gradon et al.	N/A	N/A
2007/0186931	12/2006	Zollinger et al.	N/A	N/A
2008/0041393	12/2007	Bracken	N/A	N/A
2008/0047560	12/2007	Veliss et al.	N/A	N/A
2008/0092906	12/2007	Gunaratnam et al.	N/A	N/A
2008/0223375	12/2007	Cortez et al.	N/A	N/A
2008/0275357	12/2007	Cortez et al.	N/A	N/A
2008/0295835	12/2007	Han et al.	N/A	N/A

2008/0295846	12/2007	Han et al.	N/A	N/A
2009/0000618	12/2008	Warren	N/A	N/A
2009/0025724	12/2008	Herron, Jr.	N/A	N/A
2009/0032018	12/2008	Eaton et al.	N/A	N/A
2009/0032026	12/2008	Price et al.	N/A	N/A
2009/0044808	12/2008	Guney	128/207.18	A61M 16/0875
2009/0088656	12/2008	Levitsky et al.	N/A	N/A
2009/0133697	12/2008	Kwok et al.	N/A	N/A
2009/0183739	12/2008	Wondka	N/A	N/A
2009/0320851	12/2008	Selvarajan et al.	N/A	N/A
2010/0037897	12/2009	Wood	N/A	N/A
2010/0043801	12/2009	Halling et al.	N/A	N/A
2010/0108073	12/2009	Zollinger et al.	N/A	N/A
2010/0113955	12/2009	Colman	600/538	A61M 16/085
2010/0113956	12/2009	Curti et al.	N/A	N/A
2010/0192957	12/2009	Hobson	128/207.18	A61M 16/0672
2010/0215351	12/2009	Forrester	N/A	N/A
2010/0258132	12/2009	Moore	N/A	N/A
2010/0258136	12/2009	Doherty et al.	N/A	N/A
2011/0005524	12/2010	Veliss et al.	N/A	N/A
2011/0067704	12/2010	Kooij et al.	N/A	N/A
2011/0072553	12/2010	Ho	N/A	N/A
2011/0146685	12/2010	Allan et al.	N/A	N/A
2011/0162655	12/2010	Gunaratnam	N/A	N/A
2011/0214674	12/2010	Ging et al.	N/A	N/A
2011/0232649	12/2010	Collazo et al.	N/A	N/A
2011/0265796	12/2010	Amarasinghe et al.	N/A	N/A
2011/0315148	12/2010	Widgerow et al.	N/A	N/A
2012/0013863	12/2011	Sato	N/A	N/A
2012/0125332	12/2011	Niland et al.	N/A	N/A
2012/0125338	12/2011	Yarahmadi	N/A	N/A
2012/0167894	12/2011	O'Leary	N/A	N/A
2012/0204870	12/2011	McAuley et al.	N/A	N/A
2012/0222678	12/2011	Colbaugh	N/A	N/A
2012/0234319	12/2011	Eifler	N/A	N/A
2012/0240932	12/2011	Gusky et al.	N/A	N/A
2012/0272963	12/2011	Thomas et al.	N/A	N/A
2012/0304999	12/2011	Swift et al.	N/A	N/A
2012/0305001	12/2011	Tatkov	N/A	N/A
2012/0330176	12/2011	Leow	N/A	N/A
2013/0008447	12/2012	Gunaratnam et al.	N/A	N/A
2013/0092165	12/2012	Wondka	N/A	N/A
2013/0092174	12/2012	Jackman et al.	N/A	N/A
2013/0220327	12/2012	Barlow et al.	N/A	N/A
2013/0291870	12/2012	Ging et al.	N/A	N/A

2013/0319421	12/2012	Hitchcock et al.	N/A	N/A
2014/0000626	12/2013	O'Connor et al.	N/A	N/A
2014/0053844	12/2013	Rummery et al.	N/A	N/A
2014/0102452	12/2013	Forrester	N/A	N/A
2014/0107517	12/2013	Hussain	N/A	N/A
2014/0109907	12/2013	Doshi et al.	N/A	N/A
2014/0130931	12/2013	Forrester	N/A	N/A
2014/0166015	12/2013	Waggoner	N/A	N/A
2014/0180157	12/2013	Levitsky et al.	N/A	N/A
2014/0209098	12/2013	Dunn et al.	N/A	N/A
2014/0209099	12/2013	Barker	N/A	N/A
2014/0261433	12/2013	Guney	N/A	N/A
2014/0261434	12/2013	Ng et al.	N/A	N/A
2014/0276169	12/2013	Chua	128/205.24	A61M 16/0672
2014/0283827	12/2013	Flower et al.	N/A	N/A
2014/0311494	12/2013	Gibson et al.	N/A	N/A
2014/0326395	12/2013	Forrester et al.	N/A	N/A
2014/0332108	12/2013	Forrester et al.	N/A	N/A
2015/0027443	12/2014	Barr	N/A	N/A
2015/0040898	12/2014	Breckon	N/A	N/A
2015/0068530	12/2014	Apolito	N/A	N/A
2015/0075530	12/2014	Collazo et al.	N/A	N/A
2015/0083131	12/2014	Mals	N/A	N/A
2015/0158127	12/2014	Lee et al.	N/A	N/A
2015/0196726	12/2014	Skipper et al.	N/A	N/A
2015/0208953	12/2014	Levitsky et al.	N/A	N/A
2015/0276098	12/2014	Garrett et al.	N/A	N/A
2015/0314095	12/2014	Himes, Jr. et al.	N/A	N/A
2015/0328425	12/2014	Kooij et al.	N/A	N/A
2015/0343165	12/2014	Gunartnam et al.	N/A	N/A
2016/0030696	12/2015	Klenner et al.	N/A	N/A
2016/0095997	12/2015	Kapust et al.	N/A	N/A
2016/0144146	12/2015	Huddart et al.	N/A	N/A
2016/0158476	12/2015	Tatkov	N/A	N/A
2016/0199613	12/2015	Hadas	N/A	N/A
2016/0228665	12/2015	Gulliver et al.	N/A	N/A
2016/0235936	12/2015	Frater et al.	N/A	N/A
2016/0271353	12/2015	Cheung et al.	N/A	N/A
2016/0346495	12/2015	Payton et al.	N/A	N/A
2017/0000965	12/2016	Corez, Jr. et al.	N/A	N/A
2017/0203070	12/2016	Lei	N/A	N/A
2017/0224944	12/2016	Gunaratnam et al.	N/A	N/A
2017/0296767	12/2016	White et al.	N/A	N/A
2017/0312471	12/2016	Anger et al.	N/A	N/A
2017/0333662	12/2016	Ovzinsky et al.	N/A	N/A
2018/0001045	12/2017	Cortez, Jr. et al.	N/A	N/A
2018/0021535	12/2017	Goff et al.	N/A	N/A
2018/0064899	12/2017	Ewers et al.	N/A	N/A

2018/0078726	12/2017	Barracclough et al.	N/A	N/A
2018/0093062	12/2017	Kooij et al.	N/A	N/A
2018/0099110	12/2017	Mikhael	N/A	N/A
2018/0126102	12/2017	Guney	N/A	N/A
2018/0214653	12/2017	Selvarajan et al.	N/A	N/A
2018/0289916	12/2017	Gunaratnam et al.	N/A	N/A
2018/0296786	12/2017	Barlow	N/A	N/A
2019/0275278	12/2018	Nakamura et al.	N/A	N/A
2019/0328991	12/2018	Kaszas et al.	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
2008216375	12/2007	AU	N/A
2008221506	12/2008	AU	N/A
2011313825	12/2012	AU	N/A
2012397786	12/2014	AU	N/A
2016201534	12/2015	AU	N/A
2015237807	12/2015	AU	N/A
2016222390	12/2015	AU	N/A
2017203609	12/2016	AU	N/A
2346628	12/2000	CA	N/A
472739	12/1928	DE	N/A
9213354	12/1993	DE	N/A
102006011151	12/2006	DE	N/A
102016014752	12/2017	DE	N/A
229290	12/1986	EP	N/A
0747077	12/1995	EP	N/A
1058570	12/1999	EP	N/A
1078645	12/2000	EP	N/A
1153627	12/2000	EP	N/A
1621224	12/2005	EP	N/A
1699513	12/2005	EP	N/A
1701758	12/2005	EP	N/A
1342484	12/2006	EP	N/A
1885460	12/2007	EP	N/A
2022528	12/2008	EP	N/A
2049054	12/2008	EP	N/A
2112937	12/2008	EP	N/A
2226341	12/2009	EP	N/A
2292290	12/2010	EP	N/A
2303378	12/2010	EP	N/A
2379149	12/2010	EP	N/A
2384214	12/2010	EP	N/A
2438953	12/2011	EP	N/A
1603614	12/2011	EP	N/A
2140902	12/2012	EP	N/A
2624902	12/2012	EP	N/A

2039386	12/2012	EP	N/A
2666795	12/2012	EP	N/A
2717954	12/2013	EP	N/A
2384212	12/2013	EP	N/A
2806927	12/2013	EP	N/A
1646910	12/2014	EP	N/A
2938381	12/2014	EP	N/A
2046430	12/2015	EP	N/A
3030299	12/2015	EP	N/A
3259006	12/2016	EP	N/A
1095781	12/1954	FR	N/A
2558731	12/1984	FR	N/A
2775905	12/1998	FR	N/A
704819	12/1953	GB	N/A
1293009	12/1971	GB	N/A
1419841	12/1974	GB	N/A
2493520	12/2012	GB	N/A
S4815396	12/1972	JP	N/A
3015628	12/1994	JP	N/A
2002-000748	12/2001	JP	N/A
2002-052082	12/2001	JP	N/A
562416	12/2008	NZ	N/A
571348	12/2009	NZ	N/A
550348	12/2010	NZ	N/A
584073	12/2010	NZ	N/A
586208	12/2011	NZ	N/A
591310	12/2011	NZ	N/A
594204	12/2011	NZ	N/A
595424	12/2011	NZ	N/A
587745	12/2012	NZ	N/A
603994	12/2013	NZ	N/A
605600	12/2013	NZ	N/A
615814	12/2014	NZ	N/A
623720	12/2014	NZ	N/A
623338	12/2014	NZ	N/A
626589	12/2015	NZ	N/A
630742	12/2015	NZ	N/A
709716	12/2015	NZ	N/A
630741	12/2015	NZ	N/A
706053	12/2015	NZ	N/A
714595	12/2016	NZ	N/A
715073	12/2016	NZ	N/A
713510	12/2016	NZ	N/A
733922	12/2016	NZ	N/A
720223	12/2016	NZ	N/A
722816	12/2017	NZ	N/A
725632	12/2017	NZ	N/A
WO 81/03282	12/1980	WO	N/A
WO 89/09043	12/1988	WO	N/A
WO 1997/012570	12/1996	WO	N/A

WO 97/17034	12/1996	WO	N/A
WO 1998/036687	12/1997	WO	N/A
WO 98/44973	12/1997	WO	N/A
WO 00/59567	12/1999	WO	N/A
WO-0072905	12/1999	WO	A61M 16/0666
WO 01/32250	12/2000	WO	N/A
WO 01/97892	12/2000	WO	N/A
WO 2002/005883	12/2001	WO	N/A
WO 03/006095	12/2002	WO	N/A
WO 03/066145	12/2002	WO	N/A
WO 03/068301	12/2002	WO	N/A
WO 2003/090827	12/2002	WO	N/A
WO 2004030736	12/2003	WO	N/A
WO 2005/063327	12/2003	WO	N/A
WO 2004073778	12/2003	WO	N/A
WO 2005079726	12/2004	WO	N/A
WO 2005/070063	12/2004	WO	N/A
WO 2006/120683	12/2006	WO	N/A
WO 2008/007985	12/2007	WO	N/A
WO 2009/099995	12/2008	WO	N/A
WO 2009/109005	12/2008	WO	N/A
WO 2010/084183	12/2009	WO	N/A
WO 2011/059346	12/2010	WO	N/A
WO 2011/061648	12/2010	WO	N/A
WO 2011/062510	12/2010	WO	N/A
WO 2011/121466	12/2010	WO	N/A
WO 2011/141841	12/2010	WO	N/A
WO 2013/042004	12/2012	WO	N/A
WO 2013/112545	12/2012	WO	N/A
WO 2013/138732	12/2012	WO	N/A
WO 2013/157960	12/2012	WO	N/A
WO 2014/015382	12/2013	WO	N/A
WO 2014/092703	12/2013	WO	N/A
WO 2014/142681	12/2013	WO	N/A
WO 2015/009172	12/2014	WO	N/A
WO 2015/013761	12/2014	WO	N/A
WO 2015/020540	12/2014	WO	N/A
WO 2015/145390	12/2014	WO	N/A
WO 2015/151019	12/2014	WO	N/A
WO 2015/156690	12/2014	WO	N/A
WO 2015/164921	12/2014	WO	N/A
WO 2015/192186	12/2014	WO	N/A
WO 2015/193833	12/2014	WO	N/A
WO 2016/048172	12/2015	WO	N/A
WO 2016/122716	12/2015	WO	N/A
WO 2016/133781	12/2015	WO	N/A
WO 2016/157103	12/2015	WO	N/A
WO 2016/157105	12/2015	WO	N/A
WO 2016/159787	12/2015	WO	N/A

WO 2017/004404	12/2016	WO	N/A
WO 2017/059494	12/2016	WO	N/A
WO 2017/160166	12/2016	WO	N/A
WO 2017/216650	12/2016	WO	N/A
WO 2018005851	12/2017	WO	N/A
WO 2018/108670	12/2017	WO	N/A

OTHER PUBLICATIONS

PCT International Search Report and Written Opinion; PCT/NZ2014/000163; 13 pages; dated Nov. 10, 2014. cited by applicant

Examination Report, European Patent Office, Application No. 14 833 902.1-1122, dated Mar. 6, 2019, in 3 pages. cited by applicant

European Patent Office, Extended European Search Report, Application No. 20183115.3-1122, dated Dec. 15, 2020 in 6 pages. cited by applicant

Primary Examiner: Ruddle; Elliot S

Attorney, Agent or Firm: VIA LLP

Background/Summary

INCORPORATION BY REFERENCE TO ANY PRIORITY APPLICATIONS

(1) Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.

BACKGROUND OF THE INVENTION

Technical Field of the Invention

(2) The present invention generally relates to a nasal interface. More particularly, the present invention relates to asymmetrical nasal delivery elements for a nasal interface and other arrangements for achieving asymmetric flow or partial unidirectional flow.

Description of the Related Art

(3) Humidifiers are used to provide humidified respiratory gases to a patient. Gases are delivered to the patient via a patient interface. Examples of a patient interface include an oral mask, a nasal mask, a nasal cannula, a combination of oral and nasal mask, and the like.

(4) Nasal interfaces can be used to deliver a high flow of gases to a patient. Nasal delivery elements are inserted into the nose of a patient to deliver the required therapy. The nasal delivery elements may be required to seal or semi-seal at the nose, or may not be required to seal at the nose, to deliver the therapy. Nasal high flow typically is a non-sealing therapy that delivers relatively high-volume flow to the patient through a nasal interface, which flow may be sufficient to meet or exceed the patient's inspiratory flow rate.

SUMMARY OF THE INVENTION

(5) Although prongs for nasal interfaces exist in the prior art, an aspect of at least one of the embodiments disclosed herein includes the realization that there are problems with the insertion of these prior art prongs into the nose of a patient. Prongs in the art require high motor speeds of the flow generating device to deliver the desired flow rate to the patient. A flow generating device is a device that delivers a flow of gas to a patient.

(6) If the interface is suddenly occluded, the static pressure may increase to equal the backpressure in the system, which may potentially reach undesirable levels. The undesirably high static pressure

is intensified for child and infant prongs because the reduced prong diameter required to fit the nares of a child or infant can increase resistance to flow through the interface to the patient.

(7) Currently there are few different sized nasal delivery elements available to better fit a patient, and it can be difficult to optimize dead space clearance and delivered pressure to the patient. The current options may use supplemental oxygen, require more heating, more water and may not provide a high level of patient comfort. Undesirably high flows or excessively high flows are being provided to patients to achieve the desired pressure effects with the existing interfaces. A nasal delivery element of a nasal interface with a smaller diameter may have a high leak and as a result will deliver lower pressure to a patient. A large diameter may not be as efficient at clearing anatomical dead space from the patient airways.

(8) A system is disclosed that uses nasal high flow in combination with asymmetrical nasal delivery elements for a nasal interface to deliver respiratory gases to a patient via an asymmetrical flow. Asymmetrical nasal delivery elements can provide the patient with increased dead space clearance in the upper airways, Due to a decrease in peak expiratory pressure, noise can be reduced, and asymmetrical nasal delivery elements may provide a more desirable therapy for infant use due to mitigation of the risk of completely sealing the airways of the patient. The asymmetry of the nasal delivery elements can reduce the resistance to flow through the interface, which can achieve desired flow rates using lower backpressure and/or lower motor speeds of the flow generating device.

(9) Different embodiments disclose a system that modifies the pressure effects during nasal high flow while maintaining efficient dead space clearance, by adding fittings such as but not limited to, sleeves or inserts to the nasal interface. It may increase pressure swings generated during breathing, increase jetting effects, improve patient comfort, more efficiently clear dead space and increase expiratory pressure. The use of fittings may reduce the required operational flow, which may result in less noise, reductions in heating, oxygen and water usage, desirable or optimized therapeutic effects of nasal high flow. Thus a lower flow rate may be able to achieve a higher pressure.

(10) Accordingly, in one aspect the present invention relates to a nasal interface comprising asymmetrical nasal delivery elements, the asymmetrical nasal delivery elements comprising a first nasal delivery element that is a prong and a second nasal delivery element that is a prong or a pillow, the prong or pillow of the second nasal delivery element having a greater internal cross-sectional area on a plane perpendicular to the airflow direction than a prong of the first nasal delivery element, which causes asymmetrical flow or partial unidirectional flow of gases at the nares of a subject, to improve dead space clearance, preferably to reduce the volume of anatomical dead space within the volume of the airway of a subject, to reduce peak expiratory pressure, to reduce noise, and/or to reduce resistance to flow at the patient interface.

(11) In various embodiments the first and second nasal delivery elements may comprise (1) an orifice without a nasal prong adapted in use to rest adjacent one nare and a nasal prong or a nasal pillow adapted in use to engage the other nares, or (2) a first nasal prong having a first cross-sectional area and a second nasal prong or a nasal pillow having a second cross-sectional area, the second cross-sectional area being greater than the first cross-sectional area, or (3) a first nasal prong having a first outer circumference and a second nasal prong or a nasal pillow having a second outer circumference, the second outer circumference being greater than the first outer circumference, or (4) a first nasal prong having a first cross-sectional area and a first outer circumference and a second nasal prong or a nasal pillow having a second cross-sectional area and a second outer circumference, the second cross-sectional area and second outer circumference being greater than the first cross-sectional area and first outer circumference.

(12) In various embodiments the second cross-sectional area may be about 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, 30, 30.5, 31, 31.5, 32, 32.5, 33, 33.5, 34, 34.5, 35, 35.5, 36, 36.5, 37, 37.5,

38, 38.5, 39, 39.5, 40, 40.5, 41, 41.5, 42.5, 43, 43.5, 44, 44.5, 45, 45.5, 46, 46.5, 47, 47.5, 48, 48.5, 49, 49.5, or 50 mm.sup.2, and useful ranges may be selected between any of these values (for example, about 1.5 to about 10, about 1.5 to about 20, about 1.5 to about 30, about 1.5 to about 40, and about 1.5 to about 50 mm.sup.2).

(13) In various embodiments the first cross-sectional area may be about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 78, 79, or of the second cross-sectional area, and useful ranges may be selected between any of these values (for example, about 20 to about 30, about 20 to about 40, about 20 to about 50, about 20 to about 60, about 20 to about 70, and about 20 to about 80%).

(14) In various embodiments the second cross-sectional area may be about 1.5 to about 50 mm.sup.2 and the first cross-sectional area may be about 20% to about 80% of the second cross-sectional area, preferably about 50%.

(15) In various embodiments the ratio of the first cross-sectional area to the second cross-sectional area may be at least about 1:1.2, 1:1.25, 1:1.3, 1:1.35, 1:1.4, 1:1.45, 1:1.5, 1:1.55, 1:1.6, 1:1.65, 1:1.7, 1:1.75, 1:1.8, 1:1.85, 1:1.9, 1:1.95, 1:2, 1:2.05, 1:2.1, 1:2.15, 1:2.2, 1:2.25, 1:2.3, 1:2.35, 1:2.4, 1:2.45, 1:2.5, or 1:2.5, and useful ranges may be selected between any of these values (for example, about 1:1.2 to about 1:2.5). Preferably the ratio may be about 1:2.

(16) In various embodiments the second outer circumference may be about 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23, 23.5, 24, 24.5, 25, 25.5, 26, 26.5, 27, 27.5, 28, 28.5, 29, 29.5, or 30 mm, and useful ranges may be selected between any of these values (for example, about 7.5 to about 10, about 7.5 to about 15, about 7.5 to about 20, about 7.5 to about 25, and about 7.5 to about 30 mm).

(17) In various embodiments the first outer circumference may be about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 78, 79, or 80% of second outer circumference, and useful ranges may be selected between any of these values (for example, about 20 to about 30, about 20 to about 40, about 20 to about 50/about 20 to about 60, about 20 to about 70, and about 20 to about 80%).

(18) In various embodiments the second outer circumference may be about 7.5 mm to about 30 mm and the first outer circumference may be about 20% to about 80% of the second outer circumference, preferably about 50%.

(19) In various embodiments the ratio of the first outer circumference to the second outer circumference may be at least about 1:1.2, 1:1.25, 1:1.3, 1:1.35, 1:1.4, 1:1.45, 1:1.5, 1:1.55, 1:1.6, 1:1.65, 1:1.7, 1:1.75, 1:1.8, 1:1.9, 1:1.95, 1:2, 1:2.05, 1:2.1, 1:2.15, 1:2.2, 1:2.25, 1:2.3, 1:2.35, 1:2.4, 1:2.45, or 1:2.5, and useful ranges may be selected between any of these values (for example, about 1:1.2 to about 1:2.5). Preferably the ratio may be about 1:2.

(20) In various embodiments, the nasal interface may be adapted so that fittings may be attached to the nasal delivery elements of the interface to alter the shape or inner or outer diameters of the nasal delivery elements to efficiently clear dead space, reduce operational flow, and reduce noise.

(21) In various embodiments, one nasal delivery element may comprise a single lumen, or both nasal delivery elements may comprise a single lumen.

(22) In another aspect the present invention relates to user interface assembly comprising a nasal interface as described herein, a securement system for the user interface and/or a component associated with the user interface (e.g. such as a tube or tubing), and/or a tube connected to the user interface providing at least a part of a breathing circuit for a user of the interface.

(23) In various embodiments the securement system may comprise a two-part releasable attachment (or connection) arrangement, the arrangement comprising a dermal patch and a user interface patch, (1) the dermal patch having a patient side and an interface side, (a) the patient side of the dermal patch being attachable to the skin of a user, (e.g. by an adhesive, generally being of a

dermatologically sensitive adhesive such as a hydrocolloid), (b) the interface side of the dermal patch being provided with the first part of a two-part releasable attachment or connection system, and (2) the user interface patch having an interface side and patient side, (a) the patient side of the user interface patch being provided with the complimentary second part of the two-part releasable attachment or connection system, (b) the interface side of the user interface patch being attachable (or connectable) to the user interface and/or the component associated with the user interface (e.g. a tube or tubing).

(24) In various embodiments the tube comprises (1) a tubular body, the body defining a lumen extending between open terminal ends of the body, (2) an internal form enclosed within the lumen and supportive of the tubular body, and (3) a coating encapsulating the internal form, the coating securing the internal form to the tubular body.

(25) In various embodiments the interface comprises (1) at least one nasal prong, the prong having a gas outlet adapted to be inserted into a user's nare and a gas inlet fluidly connected to the gas outlet, (2) the at least one nasal prong comprising a backing, the backing configured to rest on a user's face, wherein a lip extends about at least a part of the perimeter of a rear surface of the backing, the rear surface configured for receiving or retaining the user interface patch, such that in use, the user interface patch may be releasably attachable or connectable to, or with, the dermal patch affixed to a user's face.

(26) In various embodiments the lip is a barrier.

(27) In various embodiments the lip extends at least about the perimeter of a region substantially adjacent to a prong associated with the backing.

(28) In various embodiments the lip is an endless lip extending about the perimeter of the rear surface of the backing.

(29) In various embodiments the lip is a series of one or more separate lips.

(30) In various embodiments the one or more separate lips are adjacent or adjoining or overlapping lip portions.

(31) In various embodiments, in use, the lip substantially forms a fluid (e.g. liquid) seal, or barrier to fluid, between the rear surface of the backing and a cannula facing surface of the user interface patch.

(32) In various embodiments the backing is substantially planar or flat or contoured (such as a pre-formed curve) backing configured to rest on a user's face.

(33) In various embodiments the backing assists as a stabilizer of the prong(s) in the nare(s) of a user.

(34) In various embodiments the at least one backing extends laterally outward from the at least one nasal prong, away from the septum of a user.

(35) In various embodiments the lip(s) is hydrophobic.

(36) In various embodiments the lip(s) comprises at least one outer perimeter lip portion and at least one inner perimeter lip portion, each of said lips provided for contacting with a user's face.

(37) In various embodiments the nasal interface may further comprise (1) a face mount part comprising a base portion and the nasal delivery elements, and (2) a gases flow manifold part having a gases inlet for receiving a flow of gas from a gas source, and a gases outlet for delivering the flow of gas to the nasal delivery elements of the face mount part, the manifold part being adapted to be received by the base portion of the face mount part to fluidly connect the outlet of the manifold with the nasal delivery elements of the face mount part, and wherein the manifold part further comprises a groove at the outlet to establish a gap between the base portion of the face mount part and the manifold part, in a region of the base portion configured to locate adjacent a user's philtrum in use to thereby eliminate or at least alleviate pressure on the user's septum from the manifold part in use.

(38) In various embodiments the face mount part may comprise at least one substantially horizontal side entry passage to the interior of the base portion for releasably receiving the outlet of the

manifold part therethrough.

(39) In various embodiments the face mount part may comprise a pair of opposed side entry passages to the interior of the base portion, each adapted to releasably receive the outlet of the manifold part therethrough.

(40) In various embodiments the gases flow manifold part may be formed from a relatively harder material than the face mount part.

(41) In various embodiments the gases flow manifold part may be formed from a substantially rigid plastics material, such as polycarbonate.

(42) In various embodiments the face mount part may be formed from a substantially soft plastics material, such as silicone.

(43) In various embodiments the nasal interface may further comprise headgear comprising a strap forming a part of the headgear for assisting in retaining or stabilizing of the nasal interface upon a user, wherein the strap, or a section of the strap, to be located upon or to be placed in contact with the face or a portion of a user's face includes a surface region for frictionally engaging with the user's face, the surface region being of a relatively higher frictional surface material than the remainder of the strap forming the or a part of the headgear.

(44) In various embodiments the strap or a respective section of the strap, includes two symmetric surface regions for frictionally engaging with two symmetric portions on either side of the user's face.

(45) In various embodiments a remainder of the strap is arranged to extend as a non-facial contacting strap or section of strap which is to extend beyond the user's face or the portion of the user's face.

(46) In various embodiments, each surface region for frictionally engaging with the user's face or a portion of the user's face including the relatively higher frictional surface material assists with retaining or stabilizing of a patient interface upon the face of a user.

(47) In various embodiments each surface region comprises a material applied to the strap or the respective section of strap.

(48) In various embodiments the material applied is in the form of a sleeve positioned about the strap or the respective section of strap.

(49) In various embodiments the sleeve is configured to removeably couple about the strap or the section of the strap.

(50) In various embodiments the strap or the respective section of the strap extends through a passage in the sleeve.

(51) In various embodiments the strap or the respective section of the strap is adapted to be threaded through the passage.

(52) In various embodiments the material applied is in the form of a material coated upon the strap or the respective section of strap.

(53) In various embodiments the material applied is over-moulded upon the strap or the respective section of strap.

(54) In various embodiments the material applied is smooth and comfortable for skin contact.

(55) In various embodiments the material applied is a thermoplastic elastomer.

(56) In various embodiments each surface region is a surface of wider surface area at an end to be located more adjacent to the patient interface than the surface area of an opposing end more distant from the patient interface.

(57) In various embodiments each surface region tapers from the relatively wider surface area to the relatively lesser surface area.

(58) In various embodiments the strap or each section of the strap including the surface region further comprises a component of the strap configured to releasably couple the patient interface.

(59) In various embodiments each portion of the user's face includes a cheek of the user.

(60) In another aspect the present invention relates to a method of delivering gas to the airway of a

subject in need thereof, improving the ventilation of a subject in need thereof, reducing the volume of anatomical dead space within the volume of the airway of a subject in need thereof, and/or treating a respiratory condition in a subject in need thereof, the method comprising delivering a continuous flow of gas to the nares of a subject through a nasal interface comprising asymmetrical nasal delivery elements to generate an asymmetrical flow or a partial unidirectional flow of gases at the nares.

(61) In various embodiments the method may comprise improving the ventilation of a subject in need thereof includes reducing peak expiratory pressure, reducing noise during expiration, and/or reducing resistance to flow at the patient interface.

(62) In various embodiments the gas may be delivered to one nare of the subject at a first flow rate of about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 L/min, and useful ranges may be selected between any of these values (for example, about 5 to about 10, about 5 to about 20, about 5 to about 30, about 5 to about 40, about 5 to about 50, and about 5 to about 60 L/min).

(63) In various embodiments the flow rate to the other nare of the subject may be at a second flow rate that may be about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 78, 79, or 80% of the first flow rate, and useful ranges may be selected between any of these values (for example, about 20 to about 30, about 20 to about 40, about 20 to about 50, about 20 to about 60, about 20 to about 70, and about 20 to about 80%).

(64) In various embodiments the gas may be delivered to one nare of the subject at a first flow rate of about 5 L/min to about 60 L/min and to the other nare of the subject at a second flow rate that may be about 20% to about 80% of the first flow rate, preferably about 50%.

(65) In various embodiments the subject's mouth may be closed or sealed.

(66) In various embodiments the subject's mouth may be open.

(67) In various embodiments the method may further comprise inserting a mouthpiece into the mouth of the subject, to maintain a leak from the mouth of the subject into the atmosphere, a negative pressure line, or an expiratory limb, or to increase or control dead space clearance.

(68) In various embodiments sound generated by the expiration of gas through the nares' may be less than the sound generated by nasal expiration during nasal high flow therapy conducted at an equivalent flow rate using a nasal interface that comprises symmetrical nasal delivery elements.

(69) In various embodiments the gas pressure in the subject's airway may be estimated and/or measured.

(70) In various embodiments the average gas pressure in the subject's airway may be maintained at a level of less than about 4 cm H₂O, preferably at a level of less than about 3.5, 3, 2.5, 5 or 1 cm H₂O, preferably with the subject's mouth open or closed, preferably with the subject's mouth closed.

(71) In various embodiments the oxygen concentration of the subject's airway may be measured.

(72) In various embodiments the oxygen concentration of the subject's airway may be maintained at a substantially constant level or increased.

(73) In various embodiments the carbon dioxide concentration of the subject's airway may be measured.

(74) In various embodiments the carbon dioxide concentration of the subject's airway may be maintained at a substantially constant level or reduced.

(75) In various embodiments the molar fraction of carbon dioxide in the upper airway of the subject may be reduced, preferably by at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 molar % or more, compared to the molar fraction of carbon dioxide in the upper airway of the subject when breathing without assistance.

(76) In various embodiments the molar fraction of carbon dioxide in the upper airway of the subject may be reduced, preferably by at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 molar % or more, compared to nasal high flow therapy conducted at an equivalent flow rate using a nasal interface

that comprises symmetrical nasal delivery elements.

(77) In various embodiments the peripheral capillary oxygen saturation of the subject may be measured.

(78) In various embodiments the peripheral capillary oxygen saturation of the subject may be maintained at a substantially constant level or increased.

(79) In various embodiments herein the peripheral capillary oxygen saturation of the subject may be increased compared to nasal high flow therapy conducted at an equivalent flow rate using a nasal interface that comprises symmetrical nasal delivery elements.

(80) In various embodiments the subject may be hypoxic or hypoxemic before the method is carried out.

(81) In various embodiments the respiratory condition may be chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, or emphysema.

(82) In various embodiments the gas may be delivered to the airway of the subject for at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 90, 120, 150, or 180 minutes or more, or for at least about 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 36, 48, 60, or 72 hours or more, or for at least about 1, 2, 3, 4, 5, 6, or 7 days or more, and useful ranges may be selected between any of these values (for example, about 15 minutes to about 7 days, about 15 minutes to about 72 hours, about 15 minutes to about 180 minutes, about 30 minutes to about 7 days, about 30 minutes to about 72 hours, and about 30 minutes to about 180 minutes).

(83) In various embodiments the method may be carried out using an interface of the invention.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) These and other features, aspects, and advantages of the present invention will be described with respect to the following figures, which are intended to illustrate and not to limit the preferred embodiments.

(2) FIG. 1 is a nasal interface as known in the prior art.

(3) FIG. 2 is a nasal interface with asymmetrical nasal delivery elements.

(4) FIG. 3 is a graphical depiction of pressure and motor speed.

(5) FIGS. 4a-4n are different embodiments of a nasal interface with asymmetrical nasal delivery elements.

(6) FIGS. 5a-5f are different embodiments of a nasal interface with fittings.

(7) FIGS. 6a-6c are different embodiments of a nasal interface with different flow supplies.

(8) FIG. 7 depicts carbon dioxide rebreathing for nasal delivery elements of nasal interfaces with different inner diameters.

(9) FIG. 8 depicts pressure effects for elements of nasal interfaces with different outer diameters.

(10) FIGS. 9A-9I are different embodiments of an asymmetrical nasal interface, with one nasal delivery element having a greater internal cross-sectional area on a plane perpendicular to the airflow direction than the other nasal delivery element.

(11) FIG. 10 is an infrared image of a symmetric carbon dioxide gas stream at a flow rate of 25 L/min.

(12) FIG. 11 is an infrared image of an asymmetric carbon dioxide gas stream at a flow rate of 25 L/min.

(13) FIG. 12 shows a nasal cannula positioned in an operative position on the face of a user.

(14) FIG. 13 is a side view of the nasal cannula arrangement of FIG. 12.

(15) FIG. 14 shows the constituent assembly components of the embodiment of FIGS. 12 and 13.

(16) FIG. 15 is a front perspective view of a nasal cannula arrangement with a backing component comprising a lip.

- (17) FIG. 16 is a rear perspective view of a nasal cannula arrangement with a backing component comprising a lip.
- (18) FIG. 17 is a top rear perspective view of a nasal cannula arrangement with a backing component comprising a lip and a user interface patch on a rear surface of the backing component.
- (19) FIG. 18 is a cross sectional view through the nasal cannula arrangement of FIG. 32 when user interface patch is in connection with a dermal patch.
- (20) FIG. 19 is a side rear perspective view of the nasal cannula arrangement of FIGS. 15 to 18.
- (21) FIG. 20 is a perspective view of a face mount part of the preferred form patient interface of the invention from the outer side of the face mount part.
- (22) FIG. 21 is a perspective view of a gases flow manifold part of the preferred form patient interface of the invention.
- (23) FIG. 22 is a perspective view of the face mount part of FIG. 20 from an inner side of the face mount part.
- (24) FIG. 23 is a perspective view of the face mount part of FIG. 20 from an underside of the face mount part.
- (25) FIG. 24A is a perspective view of a preferred patient interface and headgear in an assembled state.
- (26) FIG. 24B is a perspective view of the patient interface and headgear of FIG. 24A in a disassembled state.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

- (27) Nasal interfaces (FIG. 1) can be used to deliver a high flow of gases to a patient. Nasal delivery elements, such as prongs or nasal pillows, are inserted into the nose of a patient to deliver the required therapy. The nasal delivery elements may be desired to seal or semi-seal at the nose, or may not be required to seal at the nose, to deliver the therapy. As used herein, prongs typically refer to nasal delivery elements designed to not seal or to only semi-seal at the nose, while nasal pillows typically refer to nasal delivery elements designed to seal at the nose. Nasal high flow (NHF) typically is a non-sealing therapy that delivers relatively high-volume flow to the patient through a patient interface, such as a nasal interface. A nasal interface as herein described may refer to, but is not limited to, a nasal cannula.
- (28) Disclosed is a system to deliver gases to a patient through an asymmetrical cannula interface (FIG. 2). An asymmetrical interface or asymmetrical nasal delivery elements, as described herein, refers to a interface where the nasal delivery elements differ in length (including the substantial or complete absence of a nasal delivery element), internal or external diameter, angle or form, or any combination of these. The system allows an asymmetrical flow to the delivered through the interface to both nares or to either nare. Asymmetrical flow as described herein refers to a flow that differs within the interface or within the nose. In this way, a different flow may be delivered by each nasal delivery element, or the flow may differ between inspiration and expiration, or the delivered flow may be a combination of the above. An asymmetrical flow may also include partial unidirectional flow. Delivery of asymmetrical flow may improve clearance of dead space in the upper airways, decrease peak expiratory pressure, increase safety of the therapy particularly for children and infants, and reduce resistance to flow in the interface. An asymmetrical interface, nasal delivery elements or interface as described herein includes interfaces or systems configured to produce such asymmetrical flow through asymmetrical nasal delivery elements or otherwise.
- (29) Pressure generated by NHF depends on flow through the cannula interface, the size of the nasal delivery elements and/or nares of the patient, and the breathing cycle. If flow, leak, or a combination of flow and leak, is asymmetrical through the interface, the flow through the nose may become asymmetrical during breathing. Partial or total unidirectional flow may occur and there may be improved clearance of anatomical dead space as the air is continuously flushed from the upper airways, Total unidirectional flow may be discomforting to a subject. Partial unidirectional flow may be preferred whereby less discomfort is experienced by a subject. Total unidirectional

flow as described herein occurs if flow enters one nare by a nasal delivery element and exits via the other nare via a nasal delivery element, vents to the atmosphere, due to the absence of a nasal delivery element, or the like. Partial unidirectional flow as described herein refers to flow that may enter the nose via both nares and leave the nose from one nare, flow that may enter the nose through one nare and leave the nose via both nares, or different proportions of flow that may enter the nose through both nares and different proportions of flow that may leave the nose through both nares, and is preferably flow that may enter the nose via both nares and leave the nose from one or both nares.

(30) NHF delivered through an asymmetrical cannula interface can involve making an interface in which the nasal delivery elements are of different length, internal or external diameter, or a combination of these (FIG. 2). Particularly for children or infants, nasal delivery elements will have a small internal diameter and thus higher resistance to gas flow. By using nasal delivery elements that are different lengths, each nasal delivery element may have a different internal diameter (e.g., minimum internal diameter or area). A longer nasal delivery element may have a smaller internal diameter and higher resistance to gas flow; a shorter nasal delivery element may have a larger internal diameter (e.g., larger minimum internal diameter), hence lower resistance to gas flow at the interface. A decreased resistance to flow allows the desired flow to be achieved using lower backpressure, or a lower motor speed of the gas generating device, or a combination of the two.

(31) Asymmetrical nasal delivery elements may cause the peak expiratory pressure to decrease due to the different lengths of the nasal delivery elements at the nose which may provide different internal diameters for each nasal delivery element. During exhalation a patient may be breathing against less pressure in the system as one nare may be open to the atmosphere, or a nasal delivery element may have a greater internal diameter compared to the other nasal delivery element or otherwise have less resistance to exhalation flow compared to the other nasal delivery element, which may reduce the pressure required to exhale.

(32) In an example, an asymmetrical nasal interface used with (e.g., coupled via a conduit or breathing tube) a gas generating device, such as an AIRVO™ flow generator from Fisher & Paykel Healthcare Ltd., decreases the resistance to flow. This may cause the motor speed of the AIRVO™ to drop from a range of 18,000-22,000 RPM to a range of 14,000-18,000 RPM while continuing to achieve a suitable flow for the desired therapy (e.g., NHF), such as about 8 L/min. FIG. 3 illustrates a relationship between the motor speed of the AIRVO™ flow generator and the generated backpressure in the system. The asymmetrical nasal delivery elements may cause a reduction of the backpressure generated in the system. As a result, if an interface is suddenly jammed into the nose, the maximum pressure generated will not exceed the backpressure in the system, which may improve the safety of the system during delivery of NHF.

(33) For a smaller patient, as in an infant or a child, use of asymmetrical nasal delivery elements may reduce over-insertion of both prongs into the nares, when the nares are too small with respect to the prongs, which could result in an undesired semi-seal or seal. Asymmetrical flow may be delivered to the patient even if only one prong is positioned tightly in the nose. The asymmetrical interface improves the performance of the therapy for infants as compressed gas may be used in a system without pressure control.

(34) FIGS. 4a-4n show other embodiments that include but are not limited to: nasal delivery elements with the same internal or external diameter or nasal delivery elements with a different internal or external diameter (FIGS. 4a and 4i). The nasal delivery elements may have a different form, either different from that described above, or from each other (e.g., one prong and one nasal pillow). At least one nasal delivery element may be sealed (FIGS. 4b and 4c). At least one nasal delivery element may have at least one ventilation hole. The nasal delivery elements may be symmetrical with one or more ventilation holes in at least one nasal delivery element producing asymmetrical flow during breathing (FIGS. 4d and 4n). At least one nasal delivery element may have a narrowing at the tip, which may produce asymmetrical flow through the nasal delivery

elements in a low impedance gas delivery system as a result of a pressure difference in the nose during breathing (FIG. 4j). The narrowest point may be proximal to the flow source, thus the breathing cycle may not affect flow through the asymmetrical nasal delivery elements. The interface may be designed in a way that the left and right nasal delivery elements can be swapped. The interface may have an option to divert flow through either the symmetrical or asymmetrical nasal delivery elements, to an individual nasal delivery element, by varying the resistance within the interface (FIGS. 4h and 4m), or by partial over-insertion of the into nose. The nasal delivery elements may have different lengths (FIGS. 4e and 4i), or at least one nasal delivery element may extend into the nose to the nasal valves (FIG. 4f). More than two nasal delivery elements may be used with varying internal or external diameter or with different lengths, or a combination of these (FIGS. 4g and 4k).

(35) Pressure and flow may be measured and controlled in the nares simultaneously or separately. Flow may be continuous in one nare, while it is varied in the other nare according to the breathing cycle. Different interfaces, each delivering asymmetrical flow in the nose, may be used to continuously deliver supplemental oxygen, and to deliver continuous or variable nasal high flow. One nasal delivery element may be used to deliver oxygen, gases, aerosols or the like to the patient while another nasal delivery element may be used to deliver a higher flow of air, or a different flow of oxygen, gases, aerosols or the like to the patient. Each nasal delivery element may supply different flow rates to the patient, and may connect to different flow generating elements (FIGS. 6a-6c).

(36) The system may improve the performance of NHF therapy, particularly in the therapy delivered to infants and children. It may reduce resistance compared to existing nasal interfaces and may extend and improve functionality of respiratory devices without modification of the hardware or software.

(37) Asymmetrical flow useful herein can be provided by a nasal interface using any form of pressure support, such as continuous positive airway pressure (CPAP) or non-invasive therapy (NIV). Anatomical dead space can be cleared by transnasal unidirectional flow during a therapy with increased airway pressure, where one nare may be sealed or may be used for inspiration from the apparatus without entrainment of room air and the other nare may be used for expiration (FIGS. 4b and 4c). In a different embodiment one of the nares may be left unobstructed, providing a more comfortable therapy that has lower noise than conventional NHF therapies.

(38) Asymmetrical flow may occur due to a pillow, cushion, divided mask or any other sealed nasal interface (FIGS. 4b and 4c). One nare may be connected to the inspiratory limb of a two-limbed ventilator circuit or to a breathing tube in a one-limbed circuit, such as a CPAP blower. The other nare may be left open (FIG. 4l), connected to conventional ventilation holes in the interface for biased flow, or connected to the expiratory limb in a two-limbed circuit ventilator. Connection to the expiratory limb of a ventilator may allow the use of flow variations to control the breathing in periodic breathing or Central Sleep Apnoea due to carbon dioxide clearance in the upper airway or re-breathing from the expiratory limb.

(39) Opening the mouth may decrease the pressure delivered to patient and may improve clearance of anatomical dead space. A mouthpiece may be inserted to maintain the leak, and may be further connected to a negative pressure line or the expiratory limb to increase or control clearance of dead space.

(40) To achieve comfortable asymmetrical flow, a high level of humidity, such as that delivered by the devices know as AIRVO™ or ICON™ (AIRVO™ is a humidifier with integrated flow generator device and ICON™ is a CPAP device, manufactured by Fisher & Paykel Healthcare Ltd.), may be necessary to prevent drying of the nasal epithelium. The comfort level of temperature and dew point may be determined from a ratio, and may be, but is not limited to, a range of 33° C.-37° C. and may depend on the flow rate.

(41) Different embodiments disclose a system that allows better fitting of a nasal interface into the

nares of a patient. More specifically, fittings such as, but not limited to sleeves (FIGS. 5a-5c, 5e-5f) and inserts (FIG. 5d), can be added to the nasal delivery elements of a nasal interface to optimize NHF therapy. Sleeves as described herein refer to any structure added externally to a nasal delivery element of a nasal interface. Inserts as described herein refer to any structure added internally into a nasal delivery element of a nasal interface.

(42) The NHF therapy can be improved or optimized to deliver a desired pressure profile and efficiently clear anatomical dead space. A nasal delivery element of a nasal interface with a smaller diameter may produce a jet with a higher velocity that may more efficiently clear patient dead space than a nasal delivery element with a larger diameter. Efficient clearance of dead space reduces the amount of carbon dioxide rebreathing that occurs (FIG. 7). However a larger diameter may reduce the leak that occurs around the nasal delivery elements of the nasal interface and may result in a higher delivered pressure during both inspiration and expiration (FIG. 8). A larger diameter may be more preferable in an acute setting, particularly when a patient is suffering from respiratory distress, as a higher expiratory pressure may decrease respiratory rate and improve ventilation.

(43) By adding fittings to the nasal delivery elements of the nasal interface, it is possible to have nasal delivery elements which combine a smaller inner and a larger outer diameter to improve or optimize dead space clearance while maintaining a high pressure at the same flow. FIG. 8 shows that a combination of a nasal delivery element with a large outer diameter and a smaller inner diameter may have similar pressure effects to a nasal delivery element with a large diameter and no insert, while a smaller inner diameter may provide less pressure. If the outer diameter is too large for a patient, the inspiratory pressure may become negative as the flow from may be lower than the peak inspiratory flow.

(44) It generally is not desirable to increase the wall thickness of a nasal delivery element as it may be stiff in the nose of the patient, which may damage the inner surface of the nares, causing patient discomfort. However by attaching the different fittings to the interface it may be possible to benefit from the combination of the inner and outer diameters, while still providing the patient with soft nasal delivery elements to be fitted into the nares, maintaining patient comfort.

(45) For example, by adding a sleeve onto a nasal delivery element of a nasal interface (FIGS. 5a-5b, 5e-5f), the inner diameter of the nasal delivery element remains the same and may allow jetting effects to efficiently clear the anatomical dead space, while the outer diameter has been increased to reduce the leak around the nasal delivery element and may produce higher pressure swings during breathing. The added sleeve may then be removed once the desired therapy has been delivered, or a higher pressure is no longer required. A sleeve may also function as a one-way valve which may inflate on expiration and increase expiratory pressure. To inhibit or prevent condensate accumulation a semi-permeable material may be used, a leak may be introduced, or a combination of these may be used. A sleeve may also be added to the interface to decrease the outer diameter so that it is smaller than the inner diameter (FIG. 5c), which may increase jetting effects, deviate or split the flow from the centre of the nasal delivery element to the periphery, or may combine these.

(46) A second example is to add an insert inside the nasal delivery element (FIG. 5d). This may decrease the inner diameter to reduce pressure and increase dead space clearance, while keeping the outer diameter the same. A smaller inner diameter increases jetting effects, deviates or splits the flow from the centre of the nasal delivery element to the periphery, or may combine the flow jetting effects with deviation or splitting of the flow from the centre of the nasal delivery element to the periphery.

(47) Other embodiments may include, using a fitting that may block a nasal delivery element (FIG. 5e), allowing NHF to be delivered through the unblocked nasal delivery element to the patient, using fittings that may cause asymmetrical flow to occur (FIG. 5e), or that may make an asymmetrical interface symmetrical (FIG. 5f). Adding sleeves that have been individually fit to a patient may reduce operational flow which may result in reduced noise, reduced supplemental

oxygen use, improved patient comfort, and the like. Reduced operational flow may also allow less heating, water use, and the like, to be required. Only one interface is needed per patient and it can be specifically fit to the patient to vary pressure or dead space clearance.

(48) FIG. 9 expands on embodiments described above of an asymmetrical nasal interface **100**, with one nasal delivery element **200** having a greater internal cross-sectional area **205** on a plane perpendicular to the airflow direction D than the cross-sectional area **305** of other nasal delivery element **300**. Referring to FIG. 9A, a nasal interface **100** comprises nasal delivery elements in the form of nasal prongs **200**, **300** of substantially similar length but different internal cross-sectional areas **205**, **305**. Referring to FIG. 9B, a nasal interface **100** comprises nasal delivery elements in the form of nasal prong **300** and nasal pillow **200** of substantially similar length but different internal cross-sectional areas **205**, **305**. Referring to FIG. 9C, a nasal interface **100** comprises nasal delivery elements in the form of nasal prongs **200**, **300** of different lengths and different internal cross-sectional areas **205**, **305**. Referring to FIGS. 9C and 9D, a nasal interface **100** comprises nasal delivery elements in the form of nasal prongs **200**, **300** of different lengths and different internal cross-sectional areas **205**, **305**. Referring to FIG. 9E, a nasal interface **100** comprises nasal delivery elements in the form of nasal prongs **200**, **300** of substantially similar length where nasal prong **300** narrows at its tip to have a smaller internal cross-sectional area **305** than cross-sectional area **205** of nasal prong **200**. Referring to FIG. 9F, a nasal interface **100** comprises nasal delivery elements in the form of nasal prongs **200**, **300** of substantially similar length but different internal cross-sectional areas **205**, **305**, where prong **200** comprises a meshed tip comprising a plurality of smaller orifices rather than a single opening. Referring to FIG. 9G, a nasal interface **100** comprises nasal delivery elements in the form of orifice **200** and nasal prong **300** of different internal cross-sectional areas **205**, **305**. It should be understood that in an alternative to the depicted embodiment, area **305** could be greater than area **205**. Orifice **200** is formed in the rests adjacent a user's nare. Referring to FIG. 9H, a nasal interface **100** comprises nasal delivery elements in the form of nasal prongs **200**, **300** carried on separate gas delivery conduits, that may or may not be held together in a single patient interface. Prongs **200**, **300** are of substantially similar length but different internal cross-sectional areas **205**, **305**. Referring to FIG. 9I, a nasal interface **100** comprises nasal delivery elements in the form of nasal prongs **200**, **300** of substantially similar length but different internal cross-sectional areas **205**, **305**, where the length and area of prong **200** is determined by a fitting or sleeve.

(49) FIGS. 10 and 11 are infrared photographs depicting symmetric and asymmetric flows of carbon dioxide (25 L/min).

(50) Securement System

(51) A securement system for securing a user interface and/or user tubing to a patient that is useful herein is illustrated in FIGS. 12 to 14, and is described in published international application WO2012/053910, which is hereby incorporated by reference in its entirety. The securement system **500** is illustrated supporting a nasal cannula on an infant's face comprising prongs **510**, a backing or harness **503** that is coupled to both prongs that retains the prongs in fixed spaced relation, and may be produced in different sizes to accommodate variations in nasal spacing. Backing **503** may also include housing **504** that generally encloses or captures at least a portion of the tube **501**. The housing **504** incorporates a coupling **505** that can be used to affix headgear for retaining the interface in position. A pair of outriggers **506** project outwardly from the backing **503** on either side of the tube **501**. The outriggers **506** increase a contact surface between the interface and a patient, which distributes the interface retention force over a greater area and reduces the pressure applied to a user's face. The user side face of the backing **503** and outriggers **506** (i.e., the side that rests against the face of a user) may be contoured to reflect anticipated anatomical structures. The backing **503** and the outriggers **506** also may be formed from a flexible material to allow the structure to adapt to a particular individual's face.

(52) Beneficially, the system provides for a generally more rapid and improved or simplified ease

of installation of a user interface into an operational position on a user. Further, these benefits may also contribute to improved or simplified ease of application of alternative user interfaces or removal of a user interface from a user when cycling a user between different therapies (such as gas treatments, e.g. CPAP or high-flow applications).

(53) Certain user interfaces may be provided specifically for interaction or accommodation with the system of the described embodiments. Alternatively, nonmodified user interfaces can be accommodated by the described embodiments and can also be positioned relatively easily and with a minimum of time involved in an installation procedure.

(54) In various embodiments provided by the securement system, such a system may provide for quick location of an interface to a user, and may provide for the secured positioning of the interface.

(55) The ease with which a user interface may be positioned for a user is particularly useful. Providing a system whereby a carer (e.g. nurse) is able to apply the securement system with a single hand or single handedly, particularly where the interface user is an infant, is particularly advantageous.

(56) In addition, in another embodiment, the securement system provides for a first level of securement of a user interface to a user. For example, such a first level of securement may be that as shown by FIGS. 12 to 14. Where a user requires additional or heightened security of user interface positioning or securement, a secondary level of interface securement can be utilized. Such an additional level may include application of an over patch, such as that provided, for example, by patch 660. Such a patch 660 may be an adhesive patch and can be installed over the top of the user interface and/or tubing and adhered to a portion of the dermal patch 550.

(57) The securement system 500 comprises a two-part releasable attachment or connection arrangement 551. The releasable connection arrangement 551 acts between a pair of patches that are affixed to the patient and the user interface respectively.

(58) The first patch is a dermal patch 550 that is adhered or otherwise attached to the patient's skin. The dermal patch has a user side that faces the user's skin and an interface side that faces the user interface. The user side of the dermal patch 550 may be attached to the skin of a user by a dermatologically sensitive adhesive, such as a hydrocolloid. The user interface side of the dermal patch is provided with the first part 553 of the two-part releasable attachment or connection system 551.

(59) The second patch is a user interface patch 552. The user interface patch 552 also has a patient side and an interface side. The patient side of the user interface patch 552 is disposed adjacent the dermal patch when the system 500 is engaged. The complimentary second part of the two-part releasable attachment or connection system 553 is affixed to the patient side of the user interface patch 552, so that the respective parts of the two-part releasable attachment or connection system 551 are easily engageable when the patches 550, 552 are brought together. The interface side of the user interface patch 552 is affixed to the user interface. The user interface patch may be integrated with or suitably adhered to the user interface.

(60) A part or corner of the user interface patch 552 may include a region that does not attach to the dermal patch 550. The general purpose of this is to allow a region (or tab) that can be more easily gripped by a user or carer for removing or detaching the interface from the dermal patch. For example, the backing 2004 may also comprise of such a corner region.

(61) The two-part releasable attachment or connection arrangement 551 may comprise a hook and loop material (such as Velcro™ hook and loop material), a magnet or an array of magnets disposed on the respective patches with the poles suitably arranged, an adhesive arrangement that is activated when the patches are urged together or another suitable releasable coupling. The interface side of the dermal patch 550 may have one of a hook or a loop material, and the patient side of the user interface patch 552 may have the other of the hook or loop material, such that the dermal and user interface patches are releasably attachable or connectable to each other.

(62) When we refer to a hook and loop material, we mean any one of a wide variety of area type mechanical fasteners. For example, the Velcro™ product range includes hook and loop product where the hook component includes upstanding nylon hooks (formed as cut loops through a woven backing web) which engage with any complimentary loop pile material. The Velcro™ range also includes extruded hook products, typically of a smaller size and which mate with “fluffy” non-woven fiber backing materials. These hook materials are designed to work with a range of loop substrates and in some cases, these hook materials act as loop substrates as well. Other similar systems include the Dual-Lock™ recloseable fastener system from 3M of St Paul, Minnesota USA. The common feature of these releasable fastening systems is that they engage at any part of the contact between the two parts of the system. Precise alignment of individual connectors is not required because a multitude of connectors are distributed across the area of the product. A wide range of releasable fastener systems within this field may be used in the releasable attachment system for providing releasable attachment between the dermal patch and the user interface.

(63) The first part of the two-part releasable attachment or connection system may be adhered to the user interface side of the dermal patch with a suitable adhesive and occupy up to 100% or less than about 90%, or about 85%, or about 75%, or about 60% or about 50% or about 40% or about 30% or about 20% or about 10% of the interface side surface area of the dermal patch.

(64) According to some embodiments, the dermal patch **550** is a generally planar pad having a thickness much less than both its width and its length. In some embodiments, the pad has an overall oval shape, but may take other shapes.

(65) The pad includes a first part **553** of the two-part releasable attachment system **551**. In some embodiments, the construction of the dermal patch is such that the first part **553** of the releasable attachment system comprises a substrate and multitude of fastener elements (with effective hooks, effective loops or other elements) provided across the area of the substrate. The substrate is secured to the body of the dermal patch. In some embodiments, the substrate is secured by adhesive or by direct bonding during forming of the dermal patch.

(66) In some embodiments, the substrate is smaller in area than the dermal patch and is located on the dermal patch so that it does not reach any edge of the dermal patch. In this way, the edge of the substrate is spread from the edge of the dermal patch all around the perimeter of the substrate.

(67) Nasal Cannula—First Embodiment

(68) FIGS. **15** to **19** show a nasal cannula **2000** useful herein in detail, which is also described in published international application WO2012/053910, which is hereby incorporated by reference in its entirety. Nasal cannula arrangement **2000** comprises at least one nasal prong **2001**, modified as described above, the or each prong **2001** having a gas outlet **2002** adapted to be inserted into a user's nare (or nares) and a gas inlet **2003** fluidly connected to the gas outlet **2001**. The at least one nasal prong **2001** comprises a backing **2004**, the backing **2004** configured to rest on a user's face, and where a lip **2005** extends about at least a part of the perimeter of a rear surface **2006** of the backing **2004**. The rear surface **2004** is configured for receiving or retaining a user interface patch **2007**. In use, the user interface patch **2007** may be releasably attachable or connectable to, or with, a dermal patch **2008** that is or can be affixed to a user's face.

(69) As shown by FIGS. **16** and **19**, the rear surface **2006** can be initially provided without a user interface patch, i.e. the surface **2006** is configured to receive or retain a user interface patch **2007**. Such a user interface patch **2007** may be connected to the rear surface **2006** by an adhesive or other suitable connection. Once the patch is then in position, it is ready to be connected to or receive a dermal patch.

(70) In one form, the user interface patch may be one part of a two-part connection system, for example the loops of a hook and loop system. In such an instance, the interface facing surface of a dermal patch **2008** would comprise of hooks that are engageable with the loops of the user interface patch. See FIG. **17** illustrating rear surface **2006** retaining a user interface patch with loops ready for connection to the hooks of a dermal patch.

(71) FIG. 18 shows a section through a cannula **2000** with the hooks **2009** of a dermal patch engaged with the loops **2010** of a user interface patch. Also shown is lumen **2011** or gas passage pathway for gas being supplied to the gas inlet of the cannula for delivery to the gas outlet **2002** of prongs **2001**.

(72) Nasal Cannula—Second Embodiment

(73) A patient interface useful herein is shown in **20** to **23**, and is described in unpublished international application PCT/NZ2014/000082, which is hereby incorporated by reference in its entirety.

(74) Referring to FIGS. **20** to **23**, the nasal prongs **111** and **112** are curved to extend into the patient's nares in use and to provide a smooth flow path for gases to flow through, and are modified to be asymmetric, as described above. The inner surfaces of the prongs **111** and **112** may be contoured to reduce noise. The bases of the prongs **111** and **112** may include curves surfaces to provide for smoother gases flow. This may reduce the noise level during operation.

(75) In some configurations, pads may be mounted around the base of the prongs to reduce noise. The pad may be a foam material or a mouldable material that generally conforms to the patient's nose anatomy. Soft cushions or pillows may alternatively be provided.

(76) The nasal prongs **111** and **112** are substantially hollow and substantially tubular in shape. The nasal prongs **111** and **112** may be consistent in outer diameter along their lengths but are preferably shaped to fit the contours of the nares. Each prong **111/112**, where present, has an elongate opening **111a/112a** at the distal end opposing a base portion **118** of the face mount part **110** to encourage a high flow of gases into the cavity. In alternative embodiments the nasal prongs **111** and **112** may have a tapered profile of a wider end at the base portion **118** and a narrower end at the openings **111a** and **112a**. The openings **111a** and **112a** may be scooped to direct the flow of gases up the patient's nares. The face mount portion **110** and in particular the nasal prongs **111** and **112** are preferably designed not to seal about the patient's nares to avoid excessive and potentially harmful build up of pressure during high flow therapy. The nasal prongs **111** and **112** are therefore sized to maintain a sufficient gap between the outer surface of the prongs **111** and **112** and the patient's skin to avoid sealing the gas path between the cannula **100** and patient. It should be understood that in the context of the present invention, the nasal prongs **111** and **112** are modified to be asymmetric, as described above.

(77) The face mount part **110** is shaped to generally follow the contours of a patient's face around the upper lip area. The face mount part **100** is moulded or preformed to be able to conform to and/or is pliable to adapt, accommodate and/or correspond with the contours of the user's face, in the region of the face where the cannula is to be located.

(78) The face mount part **110** comprises an elongate base portion **118** from which the nasal prongs **111** and **112** extend, and two wing portions **113** and **114** extending laterally from either side of the base portion **118**. The wing portions **113** and **114** are integrally formed with the base portion **118** but may alternatively be separate parts. An inner side **119** of the base portion **118** of the face mount part **110** is formed with an elongated oval recess **119a** configured to couple a corresponding outlet of the manifold **120**. An arcuate bridge **118a** extends from the centre of the base portion **118** to an inner wall **113a/114a** of the wings to create two horizontal side entry passages **121a** and **121b** for insertion of the outlet **123** of the manifold **120** from either side **121a** or **121b** there-through.

(79) The gases flow manifold part **120** is generally tubular in shape having a substantially annular inlet **122** at one end, and that curves around into an elongate oval outlet **123** at the opposing end. The inlet **122** is preferably removably attachable to a conduit (not shown), preferably via a threaded engagement but alternatively via a snap-fit or any other type of coupling known in the art. Alternatively, the inlet is fixedly coupled or integrally formed with a conduit. The shape of the outlet **123** corresponds with and fits into the elongate recess **119a** of the face mount part **110** with a friction fit or snap fit engagement, such that substantial force, or at least a deliberate force applied by a user or a carer, is required to separate the manifold **120** from the face mount part **110**.

(80) Desirably, the inadvertent disengagement of the manifold from the face mount part is to be avoided.

(81) An effective seal is also formed between the outlet **123** and the base portion **118** upon engagement of the two parts **110** and **120**. In particular, an outer rim or lip **126** is formed about the outlet **123** which corresponds with and sealably fits into an inner groove about the periphery of the inner recess **119a** to retain the outlet of the manifold **120** within the face mount part **110**. Upon coupling the parts **110** and **120**, the upper surface of the lip **126** engages an inner surface **119b** of the base portion **118**/surface **119b** of the recess **119a** to form an effective seal between the parts **110** and **120** for gases to flow there through. The nasal prongs **111** and **112** are aligned with corresponding apertures extending through the surface **119b** of the base portion **118** to the recess **119a** to fluidly connect the manifold outlet **123** with the nasal prongs **111** and **112** when coupled. The bridge **118a** whilst defining the entry passages **121a** and **121b** for the manifold **120**, also helps to retain the manifold **120** within the base **118** of the face mount part **110**. A corresponding indent **128** is formed on the outer surface of the outlet **123** with opposed ridges **129a** and **129b** on either side to provide a push-fit engagement mechanism between the outlet **123** and the bridge **118a** of the face mount part **110**.

(82) The exterior surface of the face mount portion and/or the wings **111** and **112** may comprises one or more channels to facilitate or allow air to flow between the lip and the cannula to cool the patient.

(83) Adhesive pads may be provided on each wing **111** and **112** to facilitate coupling of the cannula **100** to the patient—especially for younger children (e.g. under 5 years old).

(84) Each wing portion **113/114** extends laterally from the base portion **118** of the face mount part **110** and comprises an outer surface **113b/114b** configured to contact against the patient's face in use, preferably at least the upper lip region of the patient's face and slightly beyond towards the user's respective cheek. The distal ends **113c** and **114c** of the wings **113** and **114** are configured to releasably connect respective end portions **201** and **202** of a head strap **200**, described below, to retain the face mount portion **110** against the patient's face.

(85) In a preferred embodiment, each wing **113/114** comprises an integral ridge **115/116** extending transversely along the length of the wing **113/114** from the inner side of the face mount part **110** opposing the outer surface **113b/114b** of the wing **113/114**. In the preferred embodiment, each ridge **115/116** is substantially perpendicular to the outer contact surface **113b/114b** of the respective wing **113/114**. Each ridge **115/116** preferably extends from the base portion **118** of the face mount part **110** and along an upper region of the respective wing **113/114**. The ridge **115/116** acts to stabilize the face mount part **110** against the patient's face and minimize torsional stress which could otherwise cause the nasal prongs **111** and **112** to turn out and away from patient's nares. The dimensions of the ridge **115/116** including any combination of length, thickness and width (i.e. the extent to which the ridge extends away from the outer surface **113b/114b**), should be sufficient to improve the stabilization of the face mount part **110** upon the patient's face.

(86) The ridge **115/116** may be over-moulded or integrally formed with the respective wings **113/114** of the face mount part **110**.

(87) In a preferred embodiment, the distal or terminal end **113c/114c** of each wing **113/114** is accentuated or formed with a substantially greater contact surface area than a contact surface area of the wing **113/114** in the region adjacent the nasal prongs. This distal end portion **113c/114c** is preferably also angled relative to a general longitudinal axis of the face mount part **110** or base **118**. In particular, the distal end portion **113c/114c** extends obtusely away from the base **118**, or from a region of the respective wing **113/114** adjacent the base, and towards the patient's respective cheek in use. In this manner, connecting the head strap **200** to the distal end portions **113c** and **114c** of the wings **113** and **144** and wearing the interface **100** will create a substantially V-shaped structure that generates a force vector acting on the wings **113** and **114** and cannula **110** in the direction of the patient's cheeks. This has the effect of improving retention of the nasal prongs **111** and **112** within

the patient's nares and will cause the prongs **111** and **112** to turn into the nares when the distal ends **113c** and **114c** of the wings **113** and **114** are pulled by the respective ends **201** and **202** of the headgear **200**. Each distal end portion **113c/114c** may be angled smoothly or rounded or it may be angled sharply or abruptly relative to the remainder of the respective wing **113/114**.

(88) In the preferred embodiment, the distal end portion **113c/114c** is outwardly tapered to enlarge the contact surface area of the respective wing **113/114** and to also angle the distal end **113c/114c** towards the patient's cheeks.

(89) The increased surface area at the distal ends **113c** and **114c** provides added real estate for forming a suitable connection mechanism to couple the head strap **200**. In the preferred embodiment, clip retention formations **101** and **102** are provided at each distal end **113c/114c** to releasably couple dip components of the head strap **200** to the face mount portion **110** of the cannula **100**.

(90) A patient's septum and/or columella is generally quite a sensitive area and can be a source of discomfort when subjected to excessive contact pressure for prolonged periods. The present invention alleviates or reduces this pressure by providing a cushioned region of the cannula **100** adjacent the patient's septum/columella. In the preferred embodiment, the outlet **123** comprises a pair of opposed recesses or grooves **124/125** at the outer periphery for forming a dent or dip **127** in a region that locates adjacent the septum/columella in use. When coupled to the face mount portion **110**, this dip **127** creates a gap between the base portion **118** and the outlet **123** of the manifold **120**. In use, the gap cushions/softens the region of the cannula **100** directly adjacent the septum/columella. It disengages the pressure of the harder manifold part **120** from the septum/columella and allows the septum/columella to rest on the soft base of the face mount portion **110** only.

(91) The base portion **118** is preferably also formed with a hollowed outer portion and/or dipped outer profile **118b** between the prongs **111** and **112** to alleviate pressure at the septum/columella. The hollowing should be as much as possible without (significantly) compromising the flow delivered to the patient. The dipped portion **118b** is also preferably complementary to the periphery of the outlet **123** to maintain an effective seal between the two parts of the cannula.

(92) Headgear

(93) Generally, but also with reference to FIG. 24, an adjustable strap **200** the adjustment mechanism is provided in the form of one or more insertable/removable strap segments or strap extensions **220**.

(94) In an alternative embodiment, a single strap may be provided with an adjustment mechanism comprising one or more adjustment buckles, as are well known in the art, located in a central region of the strap **200** that locates adjacent the rear of the patient's head in use, or located in regions of the strap **200** that locate to the side of the patient's head, such as near end portions **201**, **202**.

(95) Strap segments **220** of a fixed length can be releasably connected to the main strap **210** to extend its length. The main strap **210** in this embodiment comprises a pair of intermediate or secondary end portions **203/204** that are releasably connectable with one another, and that are also releasably connectable with respective ends **221** and **222** of the strap segments **220**. When the secondary end portions **203** and **204** are connected to one another, the main strap **210** is of a continuous starting length/size for the wearer. To extend the length of the strap **200** beyond this starting length, the main strap **210** can be disconnected at the secondary end portions **203/204** and one or more additional strap segments **220** are connected there between.

(96) A number of strap segments **220** of varying predetermined lengths may be provided to provide alternative adjustment lengths. For example, one or more strap segments **220** may be provided having a length within the range of about 1 cm to about 10 cm, or within the range of about 2 cm to about 6 cm. The strap segments **220** have lengths of, for example, about 2 cm, about 4 cm or about 6 cm. It will be appreciated that these examples are not intended to be limiting and the length of

each strap segments can be of any size as it is dependent on the user and/or application.

(97) The additional strap segments are preferably formed from a soft and stretchable/elastic material such as an elastic, textile material/fabric that are comfortable to the wearer. For example, a tubular knitted type head strap or sections of the head straps **210** may be utilized, particular for comfort over a user's ears.

(98) It will be appreciated, particular comfort may be achieved from a head strap which is able to provide suitable locating of the patient interface in a preferred relatively stable position on a user's face, yet simultaneously provide for a relatively loose fit or low tension fit about the user's head.

(99) Alternatively, the additional strap segments may be formed from a substantially rigid material such as a hard plastics material.

(100) A strap connector **230** is provided at each of the secondary end portions **203/204** of the main strap **210** and the respective end portions **203/204** of the strap segments **220**.

(101) Each connector **230** is provided with a strap connection mechanism at one end to couple to the strap material, and a coupling mechanism at an opposing end to releasably couple the respective end of a similar connector **230**.

(102) In an alternative, the connector **230** may be various different forms of adjustable buckles suitable for adjusting the length or tension of the head strap sections **210** which hold the patient interface in position about a user's head.

(103) It will also be appreciated that the connector **230** may be located so as to be off-set from a mid-point from the rear of a user's head, or may be offset to one side of a user's head. This may be advantageous so as to avoid impinging upon a part of a user's head which may otherwise be, in some positions such as sleeping, uncomfortable for the user.

(104) In yet a further embodiment, the strap segments may be of different lengths, so as to be asymmetrically provided or to help be operational with an off-set connector **230** position. Further, it may be that of the two strap segments **210**, one of those straps may be adjustable in length while the other is not. For example, one strap segment **210** may be of a permanent length or permanently connected to the connector **230**.

(105) In a preferred embodiment, the strap connection mechanism may comprise of a series of internal teeth located within the body of the connector for establishing a friction fit engagement with the respective end of the strap. A hinged jaw of the body is provided and closes upon the teeth to securely retain the end of the strap upon the teeth. The releasable coupling mechanism at the other end comprises a pair of male and female members, such as a protrusion and aperture respectively, both adapted to connect to corresponding male and female members of a similar connector **230**. A lug on the protrusion may couple a recess in the female member to provide a snap-fit engagement between the members. It will be appreciated that in alternative embodiments, any other suitable connector configuration may be used to releasably connect the secondary end portions of the strap to one another, and to the end portions of the additional strap segments.

(106) Cannula connectors **240** are provided at the primary end portions **201** and **202** of the main strap **210**. These connectors **240** have a similar strap connection mechanism to the strap connectors **230** of the secondary end portions **203** and **204**, but include a clip member, such as a push fit clip **241**, at an end of the connector **240** opposing the strap ends. The clip **241** is configured to releasably couple the respective formation **101/102** at the side of the cannula **110**. The clip member **241** is preferably a bendable part, such as a plastic part, that forms a hinged portion relative to the strap. The clip **241** is preferably preformed to have a curved shape along its length, such as one with an angle between flat and 20 degrees for example. This curve allows the clip **241** to fit the contour of the patient's face in the region of the clip **241**.

(107) Sleeve **270** may be preformed to have a curved shape along its length, such as one with an angle between flat and 20 degrees for example. The curve allows the sleeve to fit the contour of the patient's face or cheek in the region of the sleeve in use. Alternatively the sleeve **270** may take on the shape of a curved sleeve upon engagement with the primary end portion **201/202** or connector

240 of the head strap **200**.

(108) The sleeve **270** provides a surface region of relatively higher frictional surface material for frictionally engaging with the user's face or facial skin. This surface region is to be positioned for frictional engagement with the facial cheek skin of a user. The surface region is at least localized to the strap or the section of strap which is to be positioned upon the cheeks of a user. The surface region provided with the relatively higher frictional surface material is preferably of a material that is smooth and comfortable on the skin of the patient. The sleeve **270** or at least the surface region **271** is therefore formed from a relatively softer material than the connector **240**.

(109) In one preferred embodiment, the surface region **271** or the sleeve **270** is formed from a soft Thermoplastic Elastomer (TPE), but may alternatively be formed from another plastics material such as Silicone, or any other biocompatible materials.

(110) The surface region **271** may be a surface of wider surface area more adjacent to the patient interface than the surface area more distant from the patient interface. In the preferred embodiment, the sleeve **270** tapers from a relatively wider surface area **273** to a relatively lesser surface area **274** in a direction extending away from a connection point between the connector **240** and the patient interface **100**. The width of the sleeve at the end **273** is preferably the same or similar to the width of the tapered distal end **113c/114c** of the corresponding wing portion **113/114** of the face mount part **110**. This provides a smooth transition between the patient interface **100** and the headgear **200** for improving aesthetics and achieving a visually appealing effect.

(111) Headgear for other forms of interface in addition to nasal cannula may comprise cheek supports **270** as described or similar, at or adjacent either side end of straps of headgear of the interface, which connect to the mask, for frictionally engaging with the user's face to stabilize the mask on the face at the cheeks, and particularly for example direct nasal masks comprising nozzles or pillows which enter or engage the nares of the wearer. Such headgear may again comprise a single head strap adapted to extend in use along the patient's cheeks, above the ears and about the back of the head, with ends comprising clips in any suitable form which couple to the mask on either side (or are permanently attached to the mask).

(112) Patient interfaces according to the embodiments described above may be employed in a method a method of delivering gas to the airway of a subject in need thereof, improving the ventilation of a subject in need thereof, reducing the volume of anatomical dead space within the volume of the airway of a subject in need thereof, and/or treating a respiratory condition in a subject in need thereof, as described above.

(113) Unless the context clearly requires otherwise, throughout the description and the claims, the words “comprise comprising”, and the like, are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense, that is to say, in the sense of “including, but not limited to”.

(114) Reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in the field of endeavour in any country in the world.

(115) The invention may also be said broadly to consist in the parts, elements and features referred to or indicated in the specification of the application, individually or collectively, in any or all combinations of two or more of said parts, elements or features.

(116) Where, in the foregoing description reference has been made to integers or components having known equivalents thereof, those integers are herein incorporated as if individually set forth.

(117) It should be noted that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the spirit and scope of the invention and without diminishing its attendant advantages. For instance, various components may be repositioned as desired. It is therefore intended that such changes and modifications be included within the scope of the invention. Moreover, not all of the features, aspects and advantages are

necessarily required to practice the present invention. Accordingly, the scope of the present invention is intended to be defined only by the claims that follow.

Claims

1. A nasal interface for providing a gas flow to a patient's nares, the nasal interface comprising: a first nasal delivery element and a second nasal delivery element, wherein the first nasal delivery element and the second nasal delivery element are structurally different from each other to provide an asymmetric flow of gas at the patient's nares; and wherein the first nasal delivery element and the second nasal delivery element are both configured to deliver a flow of gas to the patient's nares.
2. The nasal interface of claim 1, wherein at least one of the first nasal delivery element and the second nasal delivery element is shaped to fit contours of the patient's nares.
3. The nasal interface of claim 1, wherein at least one of the first nasal delivery element and the second nasal delivery element are sized to maintain a gap between an outer surface of each of the first nasal delivery element and the second nasal delivery element and a surface of each of the patient's nares to avoid sealing a gas path between the nasal interface and a patient.
4. The nasal interface of claim 1, wherein at least one of the first nasal delivery element and the second nasal delivery element has an elongate opening to encourage a high flow of gas into the patient's nares and/or wherein at least one of the first nasal delivery element and the second nasal delivery element has a scooped opening to direct the gas flow up the patient's nares.
5. The nasal interface of claim 1, wherein the gas flow enters a patient's nose via both nares and leaves the patient's nares from one nare.
6. The nasal interface of claim 1, wherein the gas flow enters a patient's nose through one nare and leaves the patient's nose via both nares.
7. The nasal interface of claim 1, wherein different proportions of flow enter a patient's nose through both nares and different proportions of flow leave the patient's nose through both nares.
8. The nasal interface of claim 1, wherein different proportions of flow enters a patient's nose via both nares and leaves the patient's nose from one or both nares.
9. The nasal interface of claim 1, wherein at least one of the first nasal delivery element and the second nasal delivery element comprises a sleeve or nasal pillow.
10. The nasal interface of claim 1, wherein at least one of the first nasal delivery element and the second nasal delivery element delivers gas at a flow rate of about 5 L/min to about 60 L/min.
11. The nasal interface of claim 1, wherein the gas flow is continuous or variable and/or wherein a temperature of the gas flow is between 33° C.-37° C.
12. The nasal interface of claim 1, further comprising a headgear comprising an adjustable strap.
13. The nasal interface of claim 12, wherein the adjustable strap comprises one or more insertable or removable strap segments or strap extensions.
14. The nasal interface of claim 12, wherein the adjustable strap comprises one or more adjustment buckles located in a central region of the adjustable strap.
15. The nasal interface of claim 1, wherein a first gas flow rate out of the first nasal delivery element is between 20% to 80% of a second gas flow rate out of the second nasal delivery element.
16. The nasal interface of claim 1, further comprising a face mount part comprising a base portion and the first nasal delivery element and the second nasal delivery element, the face mount part comprising at least one substantially horizontal side entry passage to an interior of the base portion.
17. The nasal interface of claim 16, further comprising a manifold part for the gas flow within the interior of the base portion, the manifold part including an outlet, the at least one substantially horizontal side entry passage having the outlet of the manifold part inserted from either side or there-through.
18. The nasal interface of claim 17, wherein the face mount part comprises one or more wing portions configured to stabilize a patient interface upon a patient's face.

19. A method of delivering gas to a patient's airway, the method comprising: delivering a flow of gas to a patient's nares through a nasal interface comprising asymmetrical nasal delivery elements to generate an asymmetrical flow of gases at the patient's nares; wherein the nasal interface comprises a first nasal delivery element and a second nasal delivery element, wherein the first nasal delivery element and the second nasal delivery element are structurally different from each other to provide an asymmetric flow of gas at the patient's nares; and wherein the first nasal delivery element and the second nasal delivery element are both configured to deliver a flow of gas to the patient's nares.
